Inmagene

News

Novel drug to tackle inflammatory diseases begins trial

An early-stage drug that is being developed to tackle inflammatory and autoimmune diseases has been approved by the US regulator.

News

Chi-Med agrees R&D partnership with Inmagene

China’s Chi-Med and Inmagene Biopharmaceuticals have agreed a strategic partnership to develop preclinical drug candidates for potential treatment of several immunological diseases.

Digital

pharmaphorum podcast Episode 231, Dr Alan Roth, Oxford Drug Design

On AI and computational support of biochemistry, with Alan R...

Dr Alan Roth, CEO of Oxford Drug Design, discusses the use of AI to accelerate discovery of new treatments.

Sales & Marketing

The AI imperative: Establishing the standard for modern clin...

The findings from the Medidata-commissioned survey confirm that AI implementation in clinical trials has moved firmly beyond theoretical discussion.

Editor's Picks